Drugs Made In America Acquisition II Corp. Ordinary Shares Cash Flow-to-Debt Ratio
Drugs Made In America Acquisition II Corp. Ordinary Shares cash flow-to-debt ratio. Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a Cash Flow-to-Debt Ratio of -0.01x as of June 2026, meaning its operating cash flow of $-172.75K could theoretically repay 0% of its total liabilities ($18.14 Million) in one year. See DMII free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2025)
Cash flow-to-debt ratio of Drugs Made In America Acquisition II Corp. Ordinary Shares from 2024 to 2025. Historical debt coverage capacity for Drugs Made In America Acquisition II Corp. Ordinary Shares across 2 annual periods. Check Drugs Made In America Acquisition II Cor cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Drugs Made In America Acquisition II Corp. Ordinary Shares Cash Flow-to-Debt Ratio by Year (2024–2025)
Drugs Made In America Acquisition II Corp. Ordinary Shares cash flow-to-debt ratio by year from 2024 to 2025. Year-by-year debt coverage analysis for Drugs Made In America Acquisition II Corp. Ordinary Shares. For the full cash flow conversion analysis, see Drugs Made In America Acquisition II Cor cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.06x | $-1.02 Million | $17.80 Million | ▲ +92.5% |
| 2024 | -0.76x | $-194.30K | $254.78K | — |